March 24, 2020 / 12:18 PM / 5 days ago

BRIEF-Novavax’ Nanoflu Achieves All Primary Endpoints In Phase 3 Clinical Trial

March 24 (Reuters) - Novavax Inc:

* NOVAVAX’ NANOFLU ACHIEVES ALL PRIMARY ENDPOINTS IN PHASE 3 CLINICAL TRIAL

* NOVAVAX INC - NOVAVAX TO SUBMIT A U.S. BLA UNDER FDA’S ACCELERATED APPROVAL PATHWAY

* NOVAVAX INC - TRIAL ALSO ACHIEVES STATISTICAL SIGNIFICANCE IN KEY SECONDARY ENDPOINTS

* NOVAVAX INC - NANOFLU WAS WELL-TOLERATED AND HAD A SAFETY PROFILE COMPARABLE TO FLUZONE QUADRIVALENT WITH A MODEST INCREASE IN LOCAL ADVERSE EVENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below